1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumorigenesis driven by BRAF(V600E) requires secondary mutations that overcome its feedback inhibition of RAC1 and migration
    Journal Article

    Gadal, S.; Boyer, J. A.; Roy, S. F.; Outmezguine, N. A.; Sharma, M.; Li, H.; Fan, N.; Chan, E.; Romin, Y.; Barlas, A.; more...
    Cancer Research (2025)

    Fulltext@MSK | Save
  • High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes
    Journal Article

    Sharifi, M. N.; Sperger, J. M.; Taylor, A. K.; Tippins, K. E.; Reese, S. R.; Carreno, V.; Kaufmann, K. R.; Chang, A. H.; Nunamaker, L. A.; Linebarger, C.; more...
    Cancer Discovery (2025)

    Fulltext@MSK | Save
  • Top advances of the year: Neoadjuvant immunotherapy in melanoma
    Editorial

    Chen, M. F.; Postow, M. A.
    Cancer (2025)

    Fulltext@MSK | Save
  • Expert consensus on treating HR+/HER2-metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists
    Journal Article

    Rugo, H. S.; Bardia, A.; Gradishar, W. J.; Hamilton, E. P.; Hurvitz, S. A.; Jhaveri, K.; Mahtani, R.; Tolaney, S. M.
    Breast (2025)

    Fulltext@MSK | Save
  • Supernumerary ring chromosome 1 syndrome leads to fusion-driven B-cell acute lymphoblastic leukemia in monozygotic twins
    Research Letter

    GutieĢrrez-Abril, J.; Gundem, G.; Fiala, E.; Liosis, K.; Farnoud, N.; Leongamornlert, D.; Amallraja, A.; Arango-Ossa, J. E.; Domenico, D.; Levine, M.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Genomic landscape of adenocarcinomas across the gastroesophageal junction moving on from the Siewert classification
    Journal Article

    Nakauchi, M.; Walch, H. S.; Nussenzweig, S.; Carr, R.; Vos, E.; Berger, M. F.; Schultz, N.; Janjigian, Y.; Wu, A.; Tang, L.; more...
    Annals of Surgery (2025)

    Fulltext@MSK | Save
  • Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC) in the monarchE trial
    Meeting Abstract

    Rubenstein, C. S.; Turner, N.; Reis, J. S.; Goetz, M. P.; Desmedt, C.; Chandarlapaty, S.; Sasano, H.; Arteaga, C. L.; Loi, S.; Graff, S. L.; more...
    Breast (2025)

    Fulltext@MSK | Save
  • Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC)
    Meeting Abstract

    Loi, S.; Johnston, S.; Arteaga, C.; Graff, S.; Chandarlapaty, S.; Goetz, M.; Desmedt, C.; Sasano, H.; Liu, D.; Rodrik-Outmezguine, V.; more...
    Breast (2025)

    Fulltext@MSK | Save
  • A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301)
    Meeting Abstract

    Hansen, A. R.; Zhang, A. Y.; Boni, V.; Mantia, C.; Yu, E. Y.; Weickhardt, A. J.; Robert, M.; Gupta, S.; Morales-Barrera, R.; Hoimes, C. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)
    Meeting Abstract

    Mak, B.; Tran, B.; Thomas, H.; Pashankar, F. D.; Hansen, A. R.; Feldman, D. R.; Huddart, R. A.; Wheater, M.; Dunwoodie, E.; Mazhar, D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save